Abhitrust 250mg Tablets for Advanced Prostate Cancer Treatment (Zytiga)

Product Introduction

Abhitrust 250mg Tablet is an indispensable oral hormonal oncology drug containing the active ingredient Abiraterone Acetate. As a potent and selective $\text{CYP}17$ inhibitor, its primary function is to suppress the production of androgens (male hormones) that drive the growth of prostate cancer cells. Abhitrust 250mg is supplied as a crucial component of the current standard of care for advanced prostate cancer management.

Uses of Abhitrust 250mg Tablet Abhitrust 250mg Tablet is indicated for use, always in combination with a low-dose corticosteroid (prednisone or prednisolone), for the treatment of:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): For men whose prostate cancer has spread to other parts of the body and has progressed despite standard androgen deprivation therapy ($\text{ADT}$).
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mHSPC): For men with newly diagnosed metastatic prostate cancer presenting with high-risk clinical features.
• Specialized Dosing: This $250\text{ mg}$ strength is specifically utilized as the reduced starting dose for patients with baseline moderate hepatic impairment (Child-Pugh Class B).

Benefits of Abhitrust 250mg Tablet Abhitrust 250mg Tablet offers significant advantages in targeted cancer therapy:

• Comprehensive Androgen Blockade: It achieves deep and profound suppression of androgen synthesis by inhibiting the $\text{CYP}17$ enzyme in all three main sites: the testes, the adrenal glands, and the tumor tissue itself.
• Proven Survival Outcomes: Clinical evidence confirms that Abiraterone Acetate significantly prolongs overall survival and delays disease progression, offering substantial clinical benefit over placebo regimens.
• Flexible Unit Dose: The $250\text{ mg}$ tablet provides the necessary unit to formulate the standard daily dosage ($\text{four }250\text{ mg}$ tablets) and allows for the critical dose adjustment required for patients with moderate liver dysfunction.

Side Effects of Abhitrust 250mg Tablet Adverse effects are primarily related to the mineralocorticoid excess caused by its mechanism, which the co-administered steroid helps to control.

• Common Side Effects: Hypertension (high blood pressure), Hypokalemia (low blood potassium), Edema (fluid retention, swelling of extremities), fatigue, joint pain/swelling, and hot flashes.
• Serious Side Effects (Requires immediate medical attention): Hepatotoxicity (severe liver injury, signs include jaundice, dark urine, or loss of appetite), Adrenocortical Insufficiency (symptoms like severe fatigue, dizziness, confusion), and cardiovascular events (e.g., irregular heartbeat).

How to Use Abhitrust 250mg Tablet

• Standard Dosage: The full daily dose of Abiraterone Acetate is $1,000\text{ mg}$ (four $250\text{ mg}$ tablets) taken as a single dose once daily, in combination with a prescribed corticosteroid (e.g., prednisone $5\text{ mg}$ orally twice daily).
• Administration: The tablets must be swallowed whole with water and should not be crushed, chewed, or split.
• Crucial Empty Stomach Rule: Abhitrust 250mg Tablet must be taken on an empty stomach. Patients must not eat food for at least two hours before and one hour after taking the dose. Taking the medication with food leads to excessive absorption and increased risk of toxicity.

How Abhitrust 250mg Tablet Works Abhitrust 250mg Tablet contains the prodrug Abiraterone Acetate, which is rapidly converted into the active compound Abiraterone. Abiraterone works as a highly selective inhibitor of the enzyme $\text{CYP}17$ (17$\alpha$-hydroxylase/$\text{C}17,20$-lyase). This enzyme is a pivotal catalyst in the biosynthesis of androgens. By blocking $\text{CYP}17$, Abiraterone profoundly reduces the synthesis of testosterone and other androgens, thereby depriving the prostate cancer cells of the necessary hormonal “fuel” for growth and proliferation and effectively slowing the disease’s progression.

• Women and Pregnancy: Abhitrust is strictly contraindicated in women, particularly those who are pregnant or may become pregnant, due to the risk of fetal harm. Women should avoid handling the tablets without protective gloves.
• Monitoring: Close and frequent monitoring of Liver Function Tests ($\text{LFTs}$), blood pressure, and serum potassium is mandatory throughout the course of treatment.
• Drug Combinations: Avoid use in combination with $\text{Radium }\text{Ra }223\text{ dichloride}$ due to increased fracture and mortality risk.
• Corticosteroid Use: Patients should not discontinue or alter the dose of the co-administered corticosteroid without consulting their physician.

What if You Forget to Take Abhitrust 250mg Tablet?

If a dose is missed, the patient should skip the missed dose entirely and continue with the next dose at the regularly scheduled time the following day. Patients must be warned not to double the dose to compensate for the missed tablet.

Quick Tips

• Strict Fasting: Adhere rigorously to the 2-hour-before/1-hour-after food restriction.
• Routine Check-ups: Regular blood pressure and blood test checks are essential for safety management.
• Contraception: Male patients with female partners of reproductive potential must use effective birth control during treatment and for three weeks after the last dose.

FAQs

Q1: What are the key considerations for bulk buyers of Abhitrust 250mg Tablet regarding product demand?

A: Demand for Abhitrust $250\text{ mg}$ is consistent and high in the oncology sector as it addresses the growing population of men with advanced prostate cancer. Its role as the base unit for the standard dose and the modified dose for liver-impaired patients makes it an essential stock item for hospital and distributor inventory across the target markets.

Q2: How does UnnatiPharmax ensure the quality and compliant delivery of Abhitrust 250mg Tablet for international distribution?

A: We assure pharmaceutical-grade quality by providing a Certificate of Analysis ($\text{CoA}$) and strict adherence to good manufacturing practices ($\text{GMP}$). Our packaging and shipping logistics ensure the product’s stability (Store below 30∘C) and full regulatory compliance for export to all specified countries.

Q3: What specific risk is associated with taking Abhitrust 250mg Tablet with food?

A: Ingestion with food, particularly high-fat meals, drastically increases the $\text{Abiraterone}$ plasma concentration, which can be unpredictable and lead to severe, dose-related toxicities, such as uncontrollable hypertension and liver enzyme elevations.

Q4: Is Abhitrust 250mg Tablet recommended for all patients with any form of prostate cancer?

A: No. It is specifically indicated for metastatic castration-resistant and metastatic high-risk castration-sensitive prostate cancer. Its use requires specialized oncology care and co-administration with a corticosteroid.

Q5: What are the risks of drug interactions with Abhitrust due to its enzyme inhibition properties?

A: Abiraterone is an inhibitor of $\text{CYP}2\text{D}6$. This can lead to increased exposure and toxicity of co-administered $\text{CYP}2\text{D}6$ substrate drugs with a narrow therapeutic index (e.g., flecainide, metoprolol). Dose adjustment of the co-administered drug is often necessary.

Q6: What is the patient management protocol for potential severe liver toxicity while on Abhitrust 250mg Tablet?

A: Patients with severe hepatotoxicity should have treatment immediately discontinued and should not be re-treated. For less severe but significant liver enzyme elevations, the drug may be temporarily interrupted and potentially re-initiated at a reduced dose upon recovery, with close monitoring.

A Note to Our Bulk Buyers:

UnnatiPharmax is committed to delivering pharmaceutical-grade Abhitrust 250mg Tablet. We provide reliable bulk supply with guaranteed efficient and fully compliant international shipping to our valued partners in Australia, Germany, Singapore, the UK, the US, and the Philippines.

References:-

• U.S. Food and Drug Administration (FDA) – Drug Label
  • Abiraterone Acetate (Zytiga) Full Prescribing Information (Includes 250mg strength): https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf
• National Institutes of Health (NIH) – MedlinePlus
  • Abiraterone Drug Information (Consumer-friendly): https://medlineplus.gov/druginfo/meds/a611046.html
• European Medicines Agency (EMA) – Product Overview (EPAR)
  • Zytiga (Brand name Abiraterone Acetate) EPAR Summary: https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga
  • Abiraterone Accord EPAR (Generic Abiraterone Acetate Product Information, includes 250mg strength details): https://www.ema.europa.eu/en/documents/product-information/abiraterone-accord-epar-product-information_en.pdf
• National Institutes of Health (NIH) – DailyMed
  • Abiraterone Acetate Labeling Information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fda6b92-59ed-4180-af68-94052a5e82cf
• National Institutes of Health (NIH) – National Cancer Institute (NCI)
  • Clinical Trials Using Abiraterone Acetate (Searchable Database of Research): https://www.cancer.gov/research/participate/clinical-trials/intervention/abiraterone-acetate?pn=1